The Jackson Laboratory has developed a new platform to provide a fast, accurate and reliable method for screening novel immunotherapy treatments for efficacy and cytokine release syndrome.

CAMBRIDGE, Mass., February 06, 2025--2seventy bio, Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene ...

While the use of chimeric antigen receptor (CAR) T-cell therapy has increased rapidly, the clinical benefit seen with these ...

Panelists discuss how real-world data on the incidence of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) compare with clinical trial findings as ...

Across all dose levels, the most common adverse events were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Grade 3 or 4 adverse events, most commonly hematologic ...

For the 86 patients included in the study, the maximum tolerated dose of FT596 was not reached, and cytokine release syndrome (CRS) was reported in just one of 18 patients treated with monotherapy ...

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

The most common adverse events across all dose levels were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Ninety-six percent of patients had grade 3 or 4 adverse ...